Laurus Labs delivered a strong Q1 FY26, with revenue up 31% YoY to ₹ 1,570 Cr.

Net Profit soared 1154% YoY to ₹ 163 Cr, driven by robust CDMO performance which grew 130% YoY in the quarter.

Gross margins hit 59.4% on a favorable product mix.

The company's diversification strategy is paying off, with non-ARV share reaching 67% in FY25. Strategic focus remains on integrated solutions, quality, and innovation, backed by significant R&D and capacity investments.

Key growth areas include expanding CDMO capabilities in small molecules, bio-fermentation, and advanced modalities like ADCs.

Recent developments include the groundbreaking of a large-scale fermentation facility in Vizag and a new finished formulation plant in Hyderabad through a JV with KRKA, committing over ₹ 500 Cr.

In Cell & Gene therapy, NexCAR19 demand is strong, and a second GMP facility is set to open in Sep 2025. A new Gene/ADC R&D and manufacturing facility is also being built in Genome Valley.

Management expects asset turnovers to normalize, with continued CAPEX of ~₹ 3,400 Cr (FY22-26) to fuel future growth.

The company maintains a healthy Net Debt-to-EBITDA of 1.2x.